Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Institutional & Insider Ownership
67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Praxis Precision Medicines has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500.
Profitability
This table compares Praxis Precision Medicines and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Praxis Precision Medicines | N/A | -29.71% | -28.46% |
| Foghorn Therapeutics | 8.40% | -10.63% | 4.53% |
Valuation and Earnings
This table compares Praxis Precision Medicines and Foghorn Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Praxis Precision Medicines | $8.55 million | 1,102.40 | -$303.27 million | ($12.93) | -26.11 |
| Foghorn Therapeutics | $30.91 million | 3.65 | -$74.28 million | ($0.98) | -1.94 |
Foghorn Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Praxis Precision Medicines and Foghorn Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Praxis Precision Medicines | 2 | 1 | 16 | 3 | 2.91 |
| Foghorn Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
Praxis Precision Medicines presently has a consensus target price of $631.68, indicating a potential upside of 87.12%. Foghorn Therapeutics has a consensus target price of $6.14, indicating a potential upside of 223.31%. Given Foghorn Therapeutics’ higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Praxis Precision Medicines.
Summary
Foghorn Therapeutics beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks.
About Praxis Precision Medicines
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
About Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that target the chromatin regulatory system, which controls how DNA is packaged and how genes are expressed. The company’s research is directed primarily toward cancer therapies, particularly for tumors driven by abnormalities in chromatin-remodeling proteins. Foghorn uses its proprietary Gene Traffic Control platform to identify and develop small-molecule treatments designed to modulate chromatin-regulating complexes.
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
